SEC Filings

Filing date Description Form View

Quarterly report which provides a continuing view of a company's financial position

 10-Q View HTML
0000950170-24-089238.pdf
0000950170-24-089238.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event

 8-K View HTML
0001193125-24-191518.pdf
0001193125-24-191518.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

 424B5 View HTML
0001193125-24-191601.pdf

Report of unscheduled material events or corporate event

 8-K View HTML
0001213900-24-054003.pdf
0001213900-24-054003.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event

 8-K View HTML
0001213900-24-052234.pdf
0001213900-24-052234.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Report of unscheduled material events or corporate event

 8-K View HTML
0001193125-24-157328.pdf
0001193125-24-157328.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Statement of changes in beneficial ownership of securities

 4 View HTML
0000950170-24-069874.pdf
0000950170-24-069874.xls

Statement of changes in beneficial ownership of securities

 4 View HTML
0000950170-24-069890.pdf
0000950170-24-069890.xls

Statement of changes in beneficial ownership of securities

 4 View HTML
0000950170-24-069887.pdf
0000950170-24-069887.xls

Statement of changes in beneficial ownership of securities

 4 View HTML
0000950170-24-069888.pdf
0000950170-24-069888.xls

Data provided by Kaleidoscope.

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video